Background and Aim

- Osteoarthritis (OA) is one of the fastest growing chronic conditions worldwide.
- Current treatments available for OA are aimed at controlling pain. There is a need for new therapies, so called Disease Modifying Osteoarthritis Drugs (DMOADs) that can prevent joint structural degeneration.

- MIV-711, a cathepsin K inhibitor, demonstrated effects versus placebo on both joint bone area and cartilage thickness following 6 months’ treatment (MIV-711-201 study presented at OARSI 2018, abstract 29).
- The aim of this study was to assess safety and efficacy measures in a subset of patients that had been included in the placebo-controlled study. All enrolled patients received six months of open-label treatment with MIV-711.

Methods

MIV-711-202 Study design

- MIV-711-201 was the initial randomised, controlled, multicentre, 3 arms, Phase II study.
- Patients were eligible for enrollment in the current MIV-711-202 extension study if they were previously enrolled in the initial placebo-controlled study and had received either 1) MIV-711 200 mg and had no clinical worsening of knee pain symptoms (group A), assessed on the Numeric Rating Scale (NRS) at the end of the treatment (OARSI92) or 2) placebo and had a clinical worsening of pain sympotms (group B) at the end of treatment assessed on the NRS (OARSI92).
- All patients in the extension study received MIV-711 200 mg once daily.
- Patients, staff and Sponsor were blinded to the prior treatment allocation in the placebo-controlled MIV-711-201 study.
- The patients remained on their usual analgesic regimen throughout the two studies.

- The placebo-controlled study employed a 4:1:2 or 3 selection method based on local radiologist assessment, with the exclusion of L 0 and L 4 as assessed by a central reader.
- Primary outcome was safety, with MRI measures as secondary outcomes and symptom and biomarker measures were assessed as exploratory outcomes.

Patient Details

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Group A</th>
<th>Group B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years) Median</td>
<td>62.0</td>
<td>62.2</td>
</tr>
<tr>
<td>Male (%</td>
<td>60.5</td>
<td>62.5</td>
</tr>
<tr>
<td>Female (%</td>
<td>39.5</td>
<td>37.5</td>
</tr>
<tr>
<td>Discontinuations</td>
<td>5 (27%)</td>
<td>9 (45%)</td>
</tr>
<tr>
<td>TEAEs in the SOC of skin</td>
<td>7 (31%)</td>
<td>9 (45%)</td>
</tr>
</tbody>
</table>
| Of the 215 patients completing the placebo-controlled study, 50 patients were enrolled in the extension study.
- Overall demographics in the extension study were similar to the placebo-controlled study.
- In this poster, for clarity and given the relative size of the groups, efficacy data is only presented for Group A (patients continuing with 200 mg MIV-711 in the extension study).

Patient study flow chart

- MIV-711 showed acceptable tolerability; overall frequency of Treatment Emergent Adverse Effects (TEAEs) was similar to that seen in the placebo-controlled study.
- A Data Monitoring Committee recommended study to proceed without modification at the two preplanned safety reviews.

- Skin (morpho) and cardiovascular events were considered Adverse Events of Special Interest (AESIs) due to prior Cathepsin K inhibitor programs.
- No cases of morpho/skleroderma and only one AESI in the SOC of skin disorders (psoriasis) were reported in the extension study.
- The frequency of cardiovascular events was judged to be within the expected range for an elderly, demographically challenged population but cardiovascular monitoring should still be considered in future studies.

Effect of MIV-711 on Joint Structure: Bone Area

- The growth in medial femur bone area was reduced compared with the historical control (placze group in the main study) with an LS Mean increase of 28.4 mm² (95%CI 13.9, 43.0) after 12 months’ treatment with MIV-711 compared with 23.2 mm² (95%CI 15.7, 30.9) after six months’ treatment with placebo.

- The normalized WOMAC scores (pain, function and stiffness) all had a continuing decline over the 12 months’ treatment with MIV-711.

Safety and Tolerability

- No treatment related serious adverse events (SAE) were reported.

- The frequency of AEs was similar between placebo and MIV-711.

- The AEs were low in frequency and severity.

- TEAEs leading to early withdrawal: 7 (31%) of 46 patients on MIV-711 and 3 (11%) of 30 patients on placebo.

- In the extension study, 50 patients were enrolled and 46 patients received MIV-711 200 mg once daily.

- No patients were withdrawn due to AEs in this study.

- The figures cover the change in Group A (n=46) in both the initial placebo-controlled study and the subsequent extension study.

- The effect on NRS average knee pain was maintained in the extension study.

Effect of MIV-711 on Biomarkers: CTX-I and CTX-II

- CTX-I and CTX-II were suppressed compared to baseline throughout the 12-month treatment period, except during the transitional inter-trial treatment interruption (approximately 10-15 days) duration.

- The increase in thickness of the femoral cartilage was 0.03 mm (95%CI -0.08, 0.14) at the end of the 12-month period compared to a decrease of 0.07 mm (95%CI -0.12, -0.01) after six months’ with placebo.

- E-diary NRS pain scores had a similar decline as to the NRS average pain scores over the 12-month period.

Discussion and Conclusions

- This study demonstrated that MIV-711 has acceptable safety and tolerability in knee OA patients, with the overall safety profile in patients completing 12 months’ treatment similar to that seen in the placebo-controlled study.
- The beneficial effects on both bone and cartilage measures as well as symptom measures that were seen in the placebo-controlled study were maintained during the second 6-month treatment period, although results must be interpreted with caution as this was an uncontrolled extension study with a limited number of patients.
- Based on these results, progression of MIV-711 into pivotal studies as a DMOAD is therefore warranted.

MEDITIV

Philip G. Conaghan1, Michael A Bowes2, Sarah R. Kingsbury1, Alan Brett1, Gwenael Guillard1, Karin Tunblad3, Torbjörn Larsson1, Åsa Holmgren1, Alli Manninen1, Karin Göhlín2, Nicolas Sjögren2, Philippa Graham3, Åsa Jansson1, Cecilia Wadell3, Richard Bethell4 and John Öhd2

1University of Leeds, UK, 2Morphosis Ltd, UK, 3Meditiv AB, Sweden